GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - EDITAS MEDICINE INC

Explicit Guidance:

• Q1 2027: Anticipated announcement of safety and tolerability data from the first cohort of the EDIT401 Phase 1/2 study.
• Second Half 2027: Anticipated release of top-level data from subsequent cohorts, including LDL cholesterol reductions, efficacy metrics, and safety/tolerability profiles.
• Cash Runway: Extended through the second half of 2028 following a $125 million financing round.

Business-Segment Outlook:

• Product Development (EDIT401): On track to dose patients in the current year (2024); strategy focuses on non-coding edits to upregulate LDL receptor (LDLR) synthesis via 3' UTR editing of the LDLR gene.
• Clinical Target Population: Initial focus on Homozygous Familial Hypercholesterolemia (HeFH) and high-risk patients with established cardiovascular disease (approx. 10 million US patients); potential expansion to non-HeFH high-risk cohorts where standard of care fails.
• Study Design: Phase 1/2 study (HORIZON context) utilizing a 3+3 dose-escalation design across at least four cohorts (minimum 3 patients per cohort); Part One covers dose escalation, Part Two covers expansion with selected dose.
• Delivery Platform: Utilization of GalNAc-dressed lipid nanoparticles (LNPs) to bypass LDLR uptake impairment in HeFH patients, leveraging the asialoglycoprotein receptor (ASGPR) for hepatocyte entry.
• Therapeutic Ambition: Aim for LDL-C reduction exceeding 50%, with a specific target goal of >60%, potentially up to 90% based on non-human primate (NHP) data durability (10-month durability observed in NHPs).

Market and Competitive Outlook:

• Market Opportunity: Addresses the ~30% of cardiovascular patients (and higher non-clinical trial population) unable to reach LDL-C targets despite aggressive standard of care (chronic combination therapy).
• Competitive Differentiation: Distinct from PCSK9 inhibitors; directly increases LDLR synthesis rather than inhibiting degradation/recycling, offering potential for deeper and more durable LDL-C knockdown.
• Regulatory Precedent: Confidence in using LDL-C as a surrogate endpoint for approval, citing final common pathway convergence with PCSK9 inhibitors, statins, and recent approvals (e.g., inclisiran) and label revisions including MACE.
• Safety Database Expectation: Anticipation of FDA requiring a safety database of a few hundred patients for HeFH approval, similar to prior precedents, with potential requirement for larger data if expanding to the broader population.

Macro / Industry Outlook:

• Regulatory Landscape: Management expects clarity on editing-specific regulatory pathways in the next couple of years, coinciding with progress from peers (e.g., Verve Therapeutics/Lilly).
• Safety Concerns: Addresses hypothetical risks of overexpressing LDLR (ER stress) and low LDL levels; cites Icelandic kindred and PCSK9 homozygous knockouts with single-digit LDL as validation of safety.
• Comorbidity Risks: Dismisses concerns regarding new-onset diabetes at very low LDL/Lp(a) levels, citing recent meta-analyses (including a Lancet analysis of millions of patient-years) indicating the risk is likely over-ascertained and close to background rates.
• Off-Target Effects: Substantial in silico, in vitro, and biochemical characterization confirms a "very clean" off-target profile.

Strategic Initiatives:

• Capital Deployment: The $125 million raised is explicitly allocated to complete Part One of the Phase 1/2 trial and progress through most enrollment of Part Two.
• Commercialization Strategy: Intention to develop and submit the optimal regulatory package independently to serve the HeFH market and potentially the broader high-risk population, rather than immediate partnership.
• Platform Evolution: Company has evolved into an exclusively in vivo CRISPR editing entity.

Risks and Headwinds to Outlook:

• Translational Risk: Reliance on the high fidelity of non-human primate data predicting human outcomes (though management views NHP data as highly predictive).
• Regulatory Uncertainty: FDA expectations regarding the specific safety database size and the acceptance of LDL-C as a primary surrogate for clinical outcomes in gene editing contexts remain subject to agency dialogue.
• Patient Selection: Efficacy and safety could vary if the GalNAc delivery mechanism faces heterogeneity in human patients with specific genetic backgrounds (though preclinical data suggests GalNAc reduces heterogeneity).
• Timing Risks: Clinical data release dates (Q1 2027 and H2 2027) are contingent on successful trial execution and cohort progression.

Management Tone on the Future:

• Confidence Level: High; management expresses strong belief in the "non-clinical translation" and the unique mechanism of action.
• Strategic Outlook: Optimistic about achieving therapeutic targets (>60% reduction) and servicing a large addressable market without immediate need for commercial partnership.
• Validation: The HORIZON study is cited as validating the critical need to target high-risk patients and the core thesis of lowering LDL-C.
• Hedging: Includes standard regulatory caveats ("contingent on regulatory agreement") and acknowledges the "hypothetical" nature of certain safety concerns while presenting data to dismiss them.